Eckert & Ziegler Reports Strong Q1 2024 Financial Growth

Eckert & Ziegler SE, a prominent TecDAX listed company, disclosed a 17% sales increase in the first quarter of 2024, reaching €67.6 million, up from €57.9 million in the previous year. Adjusted EBIT for the quarter rose by 41%, totaling €15.0 million compared to €10.6 million in the same period last year. The company also saw a significant rise in net income, registering €8.5 million, which marks a 79% increase from the €4.7 million reported in Q1 2023.

The growth was notably strong in the Medical segment, which saw a €10.4 million increase in sales, a 43% rise, primarily driven by the pharmaceutical radioisotopes business. Sales in the Isotope Products segment slightly decreased by about 2%. Despite these variances, high-margin products gained a greater share, evidencing a strategic shift towards more profitable lines. Furthermore, the company's financial forecast for 2024 remains steady, predicting sales just under €265 million and EBIT before special items around €50 million.